Goldman Sachs: Post-Q1 Healthcare Stock Allocation Becomes More Selective; Awaiting Q2 Validation

Overview

This report summarizes market sentiment and positioning shifts in China and Korea’s medical device and healthcare services sectors following Q1 earnings, based on Goldman Sachs’ recent investor conversations. The key takeaway is that despite strong Q1 performance in the CDMO segment, investor sentiment has become more selective, with most adopting a wait-and-see stance until Q2 results confirm demand recovery and margin delivery. For medical devices and healthcare services, investor interest is focused on companies with clear near-term idiosyncratic catalysts, particularly validation of 'going-global' strategies. Accordingly, Goldman Sachs has lowered average earnings forecasts for covered companies for fiscal years 2026–2028 and provided a list of preferred stocks for the second half of the year.

Core views

CDMO/CRO Segment: After a strong Q1, investors are now stepping back due to a lack of near-term catalysts. The market awaits clearer evidence from Q2 results regarding demand recovery and order visibility before turning more positive. Despite WuXi Biologics and WuXi XDC announcing share buyback programs of up to $400 million and $100 million respectively, caution persists. Additionally, headlines about U.S. restrictions on Chinese clinical data and discussions around including Chinese biotech firms in the COINS Act have added to negative sentiment, although the market generally views the short-term fundamental impact as manageable. Medical Devices & Healthcare Services Segment: Overall investor engagement remains light, with interest concentrated on companies exhibiting clear near-term idiosyncratic developments. The 'going-global' theme remains hotly debated, and investors are seeking more tangible evidence on execution, profitability, and disclosure quality before increasing exposure. Meanwhile, concerns are growing over weakness in the domestic hospital environment, as reimbursement controls continue to tighten and new anti-corruption measures implemented in May may pressure near-term activity. Earnings Forecast Adjustments: In light of evolving industry trends and company-specific developments post-Q1, Goldman Sachs has lowered its average earnings forecasts for fiscal years 2026, 2027, and 2028 by 1.8%, 2.1%, and 0.1%, respectively. Specific adjustments include: raising Frontage Holdings’ earnings forecast (laboratory services recovery better than expected); lowering forecasts for Samsung Biologics, Pharmaron, HJ Healthcare, Tigermed, Angelalign, and Weigao Group, primarily due to slower-than-expected margin recovery, rising operating costs, reimbursement pressure, or higher raw material costs. Second-Half Top Picks: 1) CDMOs/CROs: WuXi AppTec (potential Q2 guidance upgrade), Asymchem-H (GLP-1-related order momentum), Samsung Biologics (awaiting clarity on strike impacts and order inflows/capex), WuXi XDC (Singapore facility ramp-up), Tigermed (post-resolution of CSRC investigation); 2) Medical Devices & Services: Continued focus on the 'going-global' theme, including surgical robots (MicroPort MedBot, Edge Medical), clear aligners (Angelalign), and TCM services (GuShengTang).

Analysis framework

Goldman Sachs employed a combined bottom-up and top-down analytical approach. First, extensive investor feedback was gathered to capture marginal shifts in market sentiment and identify the style rotation from 'broad-based gains' to 'stock picking.' Second, macro policy risks—including U.S. geopolitical tensions, domestic DRG/DIP reimbursement controls, and new anti-corruption policies—were assessed to evaluate sector beta risk. Finally, at the company level, order trends, margin trajectories, management guidance, and specific catalysts (e.g., drug approvals, overseas capacity ramp-ups, regulatory investigation resolutions) were analyzed to identify alpha-generating stocks. This methodology underscores the emphasis on 'execution certainty' and 'visibility' in an uncertain environment.

Methodology notes

• Event Arbitrage & Behavioral FinanceExpectation Gap / Expectation Management

  Investor Sentiment and Catalyst Validation

  The report notes that investors are adopting a wait-and-see stance after strong Q1 results due to a lack of new near-term catalysts—a reflection of the market adage 'buy the rumor, sell the news' and the behavioral pattern of waiting for new validation points (e.g., Q2 orders). Understanding this dynamic helps anticipate short-term stock price volatility.

• Industry / Sector Analysis FrameworkUpstream-Midstream-Downstream Industry Chain Transmission

  Overseas Expansion Logic and Global Competition

  In medical devices and services, the report emphasizes the 'going-global' theme—Chinese companies expanding overseas to offset domestic pressures from reimbursement controls and intensifying competition. This represents a classic industry analysis perspective of seeking new growth curves through market diversification.

• Company Fundamentals & Financial FrameworkEarnings Quality Analysis

  Margin Delivery and Operating Leverage

  The report repeatedly highlights 'margin delivery' and 'operating leverage,' stressing that revenue growth alone is insufficient; actual margin improvement—especially amid capacity ramp-ups and cost pressures—is critical to assessing earnings quality.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec (2359.HK/603259.SH)

  CDMO leader benefiting from diversified growth and non-GLP-1 business validation

  Strengths

  Strong order momentum; higher proportion of late-stage and commercial projects supports margins

  Weaknesses

  GLP-1 concentration risk; geopolitical uncertainty

  Comparison

  More resilient than peers due to diversified growth

  Risks

  Geopolitical risk; pricing pressure

• Asymchem-H (6821.HK)

  Growth driven by emerging platforms (peptides, ADCs)

  Strengths

  GLP-1-related order momentum; improving TIDES capacity utilization

  Weaknesses

  Stable but slowing small-molecule demand

  Comparison

  First-mover advantage in peptides and ADCs

  Risks

  Key client loss; intensifying competition

• Samsung Biologics (207940.KS)

  Global CDMO giant with capacity expansion

  Strengths

  High utilization; global client orders; Plant 6 expansion optionality

  Weaknesses

  Recent labor disputes; order timing volatility

  Comparison

  Significant scale advantages, but exposed to global biotech financing conditions

  Risks

  Labor negotiations; slower-than-expected capacity ramp-up

• WuXi XDC (2268.HK)

  ADC outsourcing leader benefiting from ADC upcycle

  Strengths

  Demand constrained by capacity; improving late-stage/commercial visibility

  Weaknesses

  Margin volatility during ramp-up phase

  Comparison

  Unique position in the ADC sub-segment

  Risks

  Weak biotech financing; key project delays

• Tigermed (3347.HK/300347.SZ)

  CRO leader awaiting regulatory clarity

  Strengths

  Accelerated order intake in March–April; domestic innovation rebound

  Weaknesses

  AI investment drag; pricing pressure; CSRC investigation

  Comparison

  Leading domestic clinical CRO market share

  Risks

  Geopolitical risk; weak front-end demand

• MicroPort MedBot-B (2252.HK)

  Surgical robotics representative with overseas focus

  Strengths

  Strong overseas order momentum; platform model

  Weaknesses

  Long path to profitability; installation-to-revenue conversion needs validation

  Comparison

  Faster overseas progress than domestic peers

  Risks

  Overseas execution risk; uncertain reimbursement policies

• Angelalign (6699.HK)

  Clear aligner player expanding overseas

  Strengths

  Overseas breakeven achieved earlier than expected; clear case volume growth guidance

  Weaknesses

  Domestic VBP (volume-based procurement) pressure

  Comparison

  Faster overseas expansion than domestic competitors

  Risks

  Patent litigation; intensifying domestic competition

• GuShengTang (2273.HK)

  TCM services with overseas expansion and integration

  Strengths

  Resilient demand; rapid Singapore store rollout

  Weaknesses

  M&A integration risk

  Comparison

  Unique consumer-like attributes and overseas logic within healthcare services

  Risks

  M&A ROI below expectations; overseas operational risk

Key data

• Average Earnings Forecast Adjustment for FY2026–2028-1.8% / -2.1% / -0.1%Corresponding to fiscal years 2026, 2027, and 2028, reflecting sector trends and company-specific developments
• WuXi Biologics Buyback SizeUp to $400 millionAnnounced share repurchase program
• WuXi XDC Buyback SizeUp to $100 millionAnnounced share repurchase program
• GuShengTang Singapore Store Target50 stores by end-2026Overseas expansion plan; overseas revenue expected to reach ~RMB 300 million by year-end
• Angelalign 2026 Case Volume Guidance~25% growthOverseas breakeven achieved earlier than expected, supporting confidence in operating leverage

Impact & implications

The report suggests the market is transitioning from 'beta-driven' to 'alpha-focused' stock selection. For the CDMO segment, while long-term structural demand recovery remains positive, near-term confidence hinges on Q2 data, implying potential stock price consolidation pending catalysts. For medical devices and services, domestic policy headwinds (reimbursement controls, anti-corruption) reduce the appeal of pure domestic-demand stories, while companies demonstrating genuine overseas execution capability and profit improvement will command valuation premiums. Investors should lower expectations for broad sector rallies and instead focus on individual stock drivers such as order conversion, margin improvement, and overseas progress.

Risks

• U.S. restrictions on Chinese clinical data and geopolitical risks such as the COINS Act
• Continued tightening of domestic reimbursement controls (DRG/DIP)
• Short-term suppression of hospital activity due to new anti-corruption measures implemented in May
• Slow recovery in global biotech financing environment
• Rising key raw material costs (e.g., due to Middle East tensions)
• FX volatility risk

What to watch

• Q2 order trends, margin trajectories, and management guidance across companies
• Whether WuXi AppTec upgrades its Q2 guidance
• Visibility into Asymchem’s GLP-1-related projects
• Outcome of Samsung Biologics’ labor negotiations and Plant 6 capex announcements
• Order ramp-up and utilization at WuXi XDC’s Singapore facility
• Resolution of Tigermed’s CSRC investigation
• July overseas order disclosures from MicroPort MedBot and Edge Medical
• Angelalign’s overseas case growth and margin inflection point
• GuShengTang’s pace of domestic M&A and overseas store contribution